

Screening of signaling events in live cells using novel **GFP** redistribution Assays.



I.D. Goodyer*, F.R. McKenzie, S. Swinburne, A.S. Williams, K. Petersen¹, G. Hagel¹, L. Pagliaro¹, S. Bjoern¹, A. Jensen¹, A. Larsen¹, O. Thastrup¹, A.E. Jones, P. Michael, S.M. Game. Amersham Biosciences UK Limited, Amersham Place, Little Chalfont, Buckinghamshire, HP27 9NA, UK, email leadseeker@eu.amershambiosciences.com ¹BioImage AS, Moerkhoej Bygade 28. DK-2860. Soeborg. Denmark.

INTRODUCTION

The LEADseekerTM Cell Analysis System is an integrated screening system combining fast confocal line scanning with optimised software enabling real time data analysis of live cell assays at subcellular resolution. Amersham Biosciences

have collaborated with BioImage A/S, in order to develop a range of assays for proteins that undergo intracellular translocation following inhibition/stimulation. We have generated chimeric constructs using a proprietary Aequorea victoria Green Fluorescent Protein (GFP). All assays follow a similar format in that stable cell lines which express the protein:GFP chimera are generated and validated. In this poster, we present three stable cell lines expressing NF-KB-GFP, GFP-Rac-1 and GFP-PLCô-Plekstrin Homology (PH) domain chimeras. Each protein undergoes a functionally relevant translocation following activation. All assays were performed and all images were obtained and analysed on the LEADseeker Cell Analysis System.

RESULTS

In unstimulated Chinese Hamster Ovary CHO-hIR cells NFκB-GFP (p65 Rel A-GFP) is located in the cytoplasm (green fluorescence). However upon stimulation by an agonist (e.g. cytokine) the protein translocates to the nucleus (red), as shown by the appearance of a vellow signal (fig 1). NF- κ B-GFP translocates to the nucleus in a robust manner in response to a range of stimuli including IL-1 β and IL-2.

Figure 1. NF-κB translocation



Contro



Figure 1. CHO-hIR cells were stably transfected with a p65-GFP (Rel-A-GFP) construct and selected by antibiotic resistance. Cells were plated in 96 well plates (5,000 cells per well). The following day, cells were stimulated with 40 ng/ml IL-1 β for varying times. Drag5 nuclear stain (final concentration 5 µM) was added to all wells 15 minutes prior to imaging. The images shown were obtained before stimulation (control) and 40 minutes after agonist addition (stimulated).

Timecourse experiments reveal that translocation of NFκB-GFP is rapid and observable as early as 5 minutes after agonist addition (fig 2). Maximal translocation is achieved 40 minutes after agonist addition.

Figure 2. Timecourse of NF-KB translocation in response to IL-1β



Figure 2. Experiment was performed as in the legend to figure 1. Data are means +/- S.D. from a 96-well plate, > 1000 cells per determination

In unstimulated cells, the GFP-PLCô-PH domain protein is principally localised to the plasma membrane, as evidenced by the peripheral green fluorescence seen at membrane edges. Following agonist addition, the GFP-PLCδ-PH protein is seen to move away from the cell peripherv and hence the membrane (fig 3). This translocation is both rapid (occuring within seconds of agonist addition) and transient, with GFP-PLCδ-PH returning to the plasma membrane pre-stimulated state several minutes after agonist addition.

Data generated from fig 3 were analysed using a proprietary algorithm and it was found that the relative cytoplasmic intensity had increased in a reproducible fashion (fig 4).

Figure 3. PLC-PH translocation



Control

Stimulated

Figure 3. CHO-hIR cells were stably transfected with a GFP-*PLC* δ *-PH construct and selected by antibiotic resistance. Cells* were plated in 96 well plates (5,000 cells per well). The following day, cells were stimulated with ATP (300 µM). The images shown were obtained prior to (control) or 20 seconds after agonist addition (stimulated).

Figure 4. Analysis of PLC-PH translocation



Figure 4. Analysis of PLC-PH translocation from Fig 3 using LEADseeker Cell Analysis System software. Data are means +/-S.D. from a 96-well plate, > 6000 cells per determination.

In unstimulated cells, the GFP-Rac-1 protein is principally localised to the plasma membrane, as evidenced by the peripheral green fluorescence. Following agonist addition, a significant proportion of the GFP-Rac-1 protein is seen to relocate to ruffling plasma membrane (fig 5). This localisation is transient, returning to near basal levels within 20 minutes of agonist addition.

Figure 5. Rac-1 translocation









Figure 5. CHO-hIR cells were stably transfected with a GFP-Rac-1 construct and selected by antibiotic resistance. Cells were plated in 96 well plates at 5,000 cells per well. The following day, the cells were serum starved for two hours and then imaged prior to (a, c) or 7 minutes after the addition of agonist (b,d). The agonist used was either 10nM insulin (a,b) or 30nM Insulin like growth factor-I (IGF-1). Hoechst nuclear stain (final concentration 1 uM) was added to all wells 30 minutes prior to imaging.

CONCLUSIONS

The Construction of Protein:GFP chimeras using a proprietary GFP allow us to follow real time translocations of a range of molecules involved in signal transduction in live cells. We can thus bring difficult targets into the drug discovery arena.

Analysis of translocation events occurs in real-time using proprietary algorithms.

As the translocations are observed in live cells in a 96-well plate, this procedure is suitable for rapid screening of compounds that act as agonists or antagonists of the translocations.

All goods and services are sold subject to terms and conditions of sale of the company within the Amersham Biosciences group which supplies them. A copy of these terms and conditions are available on request. ©Amersham Biosciences UK Limited, 2001 - All rights reserved. Amersham Biosciences UK Limited Amersham Place Little Challont Buckinghamshire England HP79NA. Amersham Biosciences AB 85:731 84 Uppsals Swedences Inte 800 Centennial Aremu PO Box 1327 Piscataway N 08855 USA. Amersham Biosciences Europe GmbH Munzinger Strasse 9 D-79111 Freiburg Germany, Amersham Biosciences kk Sanken Building 3-25-1 Hyakunincho Shinjuku-ku Tokyo zip 169-0073 Japan

Comparation J EADseeker is a trademark of Amersham Biosciences J td or its subsidiaries. J EADseeker is covered by PCT application number WO 98/07022. Some of these products may only be available to collaborators and customers within certain of our technology access programmes This poster was presented at the 7th Annual Conference of The Society for Biomolecular Screening, 10th-13th September 2001, Baltimore, Maryland, U.S.A. *To whom all correspondence should be addresse